Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial

Martin Nyberg1,2, Daniel D. Sjoberg3, Sigrid V. Carlsson3,4,6, Ulrica Wilderäng6, Stefan Carlsson7, Johan Stranne6,8, Peter Wiklund9,10, Gunnar Steineck6, Eva Haglin11,12, Jonas Hugosson5,8 and Anders Bjartell1,2

1Department of Urology, Skåne University Hospital, Malmö, 2Division of Urological Cancers, Department of Translational Medicine, Faculty of Medicine, Lund University, Lund, Sweden, 3Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, 4Department of Surgery (Urology Service), Memorial Sloan Kettering Cancer Center, New York, NY, USA, 5Department of Urology, Institute of Clinical Sciences, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 6Department of Oncology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 7Department of Molecular Medicine and Surgery, Section of Urology, Karolinska Institute, Stockholm, 8Department of Urology, Sahlgrenska University Hospital, Gothenburg, Sweden, 9Icahn School of Medicine at Mount Sinai Health System, New York, NY, USA, 10Department of Molecular Medicine and Surgery Section of Urology, Karolinska Institute, Stockholm, 11Department of Surgery, Institute of Clinical Sciences, Scandinavian Surgical Outcomes Research Group, Sahlgrenska Academy, University of Gothenburg, Gothenburg, and 12Department of Surgery, Region Västra Götaland, Sahlgrenska University Hospital/Ostra, Gothenburg, Sweden

Objectives

To evaluate how surgeon heterogeneity – the variation in outcomes between individual surgeons – influences functional and oncological outcomes after robot-assisted laparoscopic prostatectomy (RALP) and retropubic radical prostatectomy (RRP), and to assess whether surgeon heterogeneity affects the comparison between RALP and RRP.

Patients and Methods

Laparoscopic Prostatectomy Robot Open (LAPPRO) is a prospective, controlled, non-randomized trial performed at 14 Swedish centres with 68 operating surgeons. A total of 4003 men with localized prostate cancer were enrolled between 2008 and 2011. The endpoints were urinary incontinence, erectile dysfunction (ED) and recurrence at 24 months after surgery. Logistic regression models were built to evaluate surgeon heterogeneity and, secondarily, surgeon-specific factors were added to the models to investigate their influence on heterogeneity and the comparison between RALP and RRP.

Results

Among surgeons who performed at least 20 surgeries during the study period (n=25), we observed statistically significant heterogeneity for incontinence (P = 0.001), ED (P < 0.001) and rate of recurrent disease (P < 0.001). The significant heterogeneity remained when analysing only experienced surgeons with a stated experience of at least 250 radical prostatectomies (n=12). Among all participating surgeons (n=68), differences in surgeon volume explained 42% of the observed heterogeneity for incontinence (P = 0.003), 11% for ED (P = 0.03) and 19% for recurrence (P = 0.01). Taking surgeon volume into account when comparing RALP and RRP had a significant impact on the results. The effect was greatest for functional outcomes, and the additional adjustments for the surgeons’ previous experience changed whether the difference between techniques was statistically significant or not. The surgeons’ annual volume had the greatest effect on the recurrence rate.

Conclusions

There was a large degree of heterogeneity among surgeons regarding both functional and oncological outcomes and this had a significant impact on the results when comparing RALP and RRP. Some of the observed heterogeneity was explained by differences in surgeon volume. Efforts to decrease heterogeneity are warranted and variation among surgeons must be accounted for when conducting comparative analyses between surgical techniques.

Keywords

biochemical recurrence, erectile dysfunction, prostate cancer, radical prostatectomy, surgeon heterogeneity, urinary incontinence
Introduction

Radical prostatectomy (RP) has become one of the most common urological operations [1]. The randomized Scandinavian Prostate Cancer Group trial (SPCG-4) showed a reduction in prostate cancer mortality after 29 years of follow-up, with a mean gain of 2.9 life-years with RP compared with watchful waiting [2]. However, RP is associated with long-term complications such as urinary incontinence and erectile dysfunction (ED) [3], which have a major impact on patients’ quality of life [2,4,5]. During the last decades, the traditional surgical approach, retropubic radical prostatectomy (RRP) has been challenged by robot-assisted laparoscopic prostatectomy (RALP) and today RALP is more common in many countries than RRP. The extensive use of RALP, however, is not supported by strong evidence of superior functional and oncological outcomes compared to RRP [6–14]. In addition, the role of the individual surgeons’ experience and skill, in relation to incontinence, impotence and recurrence rate after surgery is poorly described. Previous studies have reported significant heterogeneity among surgeons [15–17], but few studies have reported on underlying factors and, to our knowledge, no study has investigated the effect of surgeon heterogeneity when comparing between RALP and RRP.

The Laparoscopic Prostatectomy Robot Open (LAPPRO) trial is a prospective, controlled, non-randomized multicentre trial comparing outcomes after RALP and RRP. The primary endpoint of urinary incontinence rate was assessed at 12 and 24 months after surgery, showing no statistically significant differences between surgical methods. For ED a small and statistically significant difference in favour of RALP was observed, while no significant differences were observed for oncological outcomes [6,18]. Analyses were restricted to surgeons with experience of at least 100 RPs, but differences among individual surgeons such as previous experience and annual caseload were not accounted for.

The aim of the present study was to describe heterogeneity among all participating surgeons in relation to functional and oncological outcomes in the LAPPRO trial, with 24 months’ follow-up. We also sought to investigate which underlying surgeon-dependent factors were of importance, and how surgeon heterogeneity influenced the results when comparing functional and oncological outcomes between RRP and RALP.

Patients and Methods

Study Design and Participants

The design of the LAPPRO trial has been reported in detail [6,19]. Fourteen Swedish centres, seven performing RRP and seven RALP, participated during September 2008 to November 2011. This analysis was restricted to patients with the following criteria: age <75 years; clinical tumour stage ≤T3; PSA concentration at baseline <20 ng/mL; and no signs of distant metastasis. The study was approved by the Regional Ethical Review Board in Göteborg (no 277-07). The trial is registered in the Current Controlled Trials database (ISRCTN 06393679).

Data were collected by patient questionnaires before surgery as well as 3, 12 and 24 months postoperatively. Clinical information from outpatient hospital visits was collected on a peri-operative case record form and at the same intervals as mentioned above. Each surgeon’s previous experience (number of either RRPs or RALPs performed) was obtained from the peri-operative case record form on which each surgeon stated their surgical experience in categories (0–49, 50–99, 100–150, or more than 150 procedures). Surgeons who had performed more than 150 procedures were contacted retrospectively and asked for the total number of RPs performed (RRPs or RALPs) before entering the LAPPRO trial.

Outcome Measurements

The endpoints were urinary incontinence, ED and recurrence at 24 months after surgery. We used the same definitions as previously published [18]. Incontinence was defined according to the number of pads used during a typical 24-h period and ED according to question 3 of the International Index of Erectile Function. Men who reported use of intracorporeal or intra-urethral injections of alprostadil were considered impotent. Recurrence (combination of residual disease and biochemical recurrence) was defined as a measurable PSA level >0.25 ng/mL at 3-, 12- or 24-month follow-up, and/or postoperative treatment with radiotherapy, androgen deprivation therapy or chemotherapy. Patients with missing data on functional outcomes at 24 months who reported being potent/continent at 3 and 12 months after surgery, were considered potent/continent after 24 months.

Statistical Analysis

To evaluate the surgeon-specific heterogeneity for each outcome measure, we built logistic regression models and included surgeons with at least 20 surgeries during the study period as a fixed effect. The model was used to create a forest plot and to test for surgeon heterogeneity (likelihood ratio test). For each outcome, we built a model adjusted for baseline patient and tumour characteristics to account for potential differences in the case mix of patients operated on by different surgeons. As a subgroup analyses, analyses were repeated for surgeons with experience of at least 250 RPs. We also analysed whether a correlation between the three outcomes existed using Spearman’s correlation.

To quantify heterogeneity among all participating surgeons we used mixed-effects logistic regression models including surgeon as a random intercept. The model estimated the
standard deviation among the surgeons’ outcomes. A large standard deviation indicated dissimilar outcomes among surgeons. We investigated how three different surgeon-dependent factors modified the observed surgeon heterogeneity among the three outcome variables: the degree of nerve-sparing surgery (bilateral, unilateral or no); a surgeon’s experience according to number of RPs performed prior to the current procedure; and the annual caseload of procedures during the study. Each of these factors was added to the base models, and the change as percentage of the standard deviation was recorded. Large changes indicated the factor was related to much of the observed heterogeneity.

For both functional and oncological outcomes, the base models were adjusted for the same potential confounders as in previous LAPPRO publications [6,18]. For urinary incontinence, the base models were adjusted for age at surgery, incontinence at baseline, body mass index (≥30 vs <30 kg/m²), history of inguinal hernia, history of abdominal surgery, diabetes, history of lung disease, history of mental disease, pathology prostate weight (0–19, 20–39, 40–59, 60–79, ≥80 g), clinical T-stage (cT1, cT2, cT3), preoperative PSA (0–4.4, 4.5–6.1, 6.2–9.1, 9.2–20 ng/mL), biopsy Gleason score (4–7 vs 8–10), and length of cancer in biopsy core (0–3.7, 3.8–7.6, 7.7–15.9, ≥16 mm). ED models were adjusted for age at surgery, baseline potency, diabetes, history of inguinal hernia, smoking (never, former, current), history of cardiovascular disease, relationship status, clinical T-stage, preoperative PSA, biopsy Gleason score, and length of cancer in biopsy core. Models for recurrence included pathology prostate weight, pathology T-stage (pT1, pT2, pT3), preoperative PSA level, and prostatectomy Gleason score. For the subgroup analyses of experienced surgeons we created an additional model where, in addition to adjustments for baseline patient and tumour characteristics, we also adjusted for the surgeons’ annual caseload.

We also undertook analyses to assess whether surgeon-dependent factors modified our assessment of RALP vs RRP. The mixed-effects models described above were repeated including a covariate for the type of surgery performed.

All analyses were repeated excluding surgeons who performed fewer than 20 surgeries during the LAPPRO trial to assess whether any reported results were sensitive to including the lowest-volume surgeons. All analyses were conducted using R 3.5 (R Foundation for Statistical Computing, Vienna, Austria) with the lme4 package [20].

Results
Of 4003 patients included in the LAPPRO trial, 3443 were evaluable for the present analyses, 2617 after RALP and 826 after RRP (Fig. 1). Patient and tumour characteristics are shown in Table 1. The RPs were performed by 68 surgeons. Those operating with a robot-assisted technique were less experienced (median [interquartile range] 62 [19–132] vs 148

![Fig. 1 Enrolment. Numbers may not sum up, as the same participant may have fulfilled more than one exclusion criterion. CRF, case record form.](image-url)
[99–388] procedures), but had a higher annual caseload (median [interquartile range] 41 [27–61] vs 6 [3–12] cases) than surgeons operating with the open technique. RALP procedures were more often nerve-sparing compared with RRP (Table 1).

Table 1 Patient, tumour and surgeon characteristics.

| Variable                        | RALP N = 2617 | RRP N = 826 | P  
|---------------------------------|---------------|-------------|----- 
| Age at surgery, years           | 63 (58, 67)   | 63 (59, 67) | 0.4  
| Preoperative PSA, ng/mL         | 6.0 (4.5, 8.8)| 6.3 (4.5, 9.1)| 0.13  
| Clinical T-stage, n (%)         |               |             |     
| T1                              | 1547 (59)     | 547 (66)    | <0.001  
| T2                              | 994 (38)      | 250 (30)    |     
| T3                              | 76 (2.9)      | 29 (3.5)    |     
| T4                              | 0 (0)         | 0 (0)       |     
| Biopsy Gleason score, n (%)     |               |             |     
| 4–7                             | 2455 (94)     | 777 (94)    | >0.9  
| 8–10                            | 150 (5.8)     | 48 (5.8)    |     
| Unknown                         | 12            | 1           |     
| Pathological T-stage, n (%)     |               |             |     
| T1                              | 0 (0)         | 0 (0)       | 0.6  
| T2                              | 1852 (72)     | 603 (74)    |     
| T3                              | 696 (27)      | 210 (26)    |     
| T4                              | 10 (0.4)      | 4 (0.5)     |     
| Unknown                         | 59            | 9           |     
| Pathological Gleason score, n (%)|           |             |     
| 4–7                             | 2402 (93)     | 772 (94)    | 0.3  
| 8–10                            | 179 (6.9)     | 47 (5.7)    |     
| Unknown                         | 36            | 7           |     
| Path. prostate weight, g        | 42 (34, 53)   | 44 (36, 54) | >0.001  
| Unknown                         | 32            | 12          |     
| Nerve-sparing status, n (%)     |               |             |     
| None                            | 813 (31)      | 336 (41)    | <0.001  
| Unilateral                      | 1012 (39)     | 194 (24)    |     
| Bilateral                       | 790 (30)      | 294 (36)    |     
| Unknown                         | 2             | 2           |     
| BMI, kg/m²                      | 26 (24, 28)   | 26 (24, 28) | 0.042  
| Unknown                         | 346           | 117         |     
| Smoking status, n (%)           |               |             |     
| Never                           | 914 (40)      | 302 (42)    | 0.3  
| Former                          | 1165 (51)     | 357 (50)    |     
| Current                         | 224 (9.7)     | 59 (8.2)    |     
| Unknown                         | 314           | 108         |     
| Cardiovascular disease, n (%)   | 800 (35)      | 247 (35)    | >0.9  
| Unknown                         | 319           | 111         |     

BMI, body mass index; RALP, robot-assisted laparoscopic prostatectomy; RRP, retropubic radical prostatectomy. Values are presented as median (interquartile range), unless otherwise indicated.

Surgeon Heterogeneity and Outcomes

Among participating surgeons with at least 20 surgeries during the study period (n=25) the incontinence rate varied from 5% to 30%, representing statistically significant heterogeneity (P = 0.001). The rate of ED varied from 61% to 93% (P < 0.001) and recurrent disease from 4% to 35% (P < 0.001; Fig. 2a–c).

For surgeons who had performed more than 250 RPs (n=12), statistically significant heterogeneity was found for rate of incontinence (P = 0.008), rate of ED (P < 0.001) and recurrence rate (P = 0.03). By adding adjustment for annual caseload, statistically significant heterogeneity was found for incontinence rate (P = 0.009) and rate of ED (P < 0.001), whereas heterogeneity for recurrence rate was no longer significant (P = 0.8).

There were no statistically significant correlations between the outcomes (incontinence and ED, r = −0.001, P > 0.9; incontinence and recurrence rate, r = −0.25, P = 0.2; ED and recurrence rate, r = 0.23, P = 0.3).

Surgeon-Dependent Factors

The surgeons’ prior experience, annual caseload and degree of nerve-sparing were analysed separately and in combination, and the change was recorded as a percentage of the standard deviation.

Surgeons’ experience accounted for 42% of observed heterogeneity regarding incontinence (P = 0.003) and 11% regarding ED (P = 0.03), but did not significantly influence recurrence. The degree of nerve-sparing explained 5% of heterogeneity in both incontinence and ED (P = 0.002 and P ≤0.001, respectively), but did not significantly change recurrence heterogeneity. Annual caseload did not significantly influence either incontinence or ED (nonsignificant) but accounted for 19% of heterogeneity regarding recurrence (P = 0.01).

To assess whether the comparison of surgical technique was affected when the surgeons’ previous experience, annual caseload and degree of nerve-sparing surgery were taken into account, analyses were repeated including a covariate for the type of surgery performed (Fig. 3a–c).

In the base model, only adjusting for differences in patient and tumour characteristics, the difference between techniques in incontinence rate was statistically significantly lower after RRP than after RALP (Fig. 3a). Adjusting for annual caseload increased the difference between techniques, whereas adjustments for previous experience reduced the difference in incontinence rate to a statistically nonsignificant level.

Regarding ED there was no statistically significant difference between techniques at baseline (Fig. 3b), but adjusting for previous experience of surgeons resulted in a statistically significant difference in favour of RALP. Adjustment for annual caseload or nerve-sparing made the techniques more similar.

Regarding recurrence rate, no statistically significant difference was seen between surgical techniques in the base model (Fig. 3c), and the additional adjustments did not change this.

The results remained largely unchanged when analyses were repeated and surgeons who performed fewer than 20 surgeries during the study period were excluded (nonsignificant).
Discussion

In the present study, we analysed surgeon heterogeneity from three different perspectives: (i) how it affected functional and oncological outcomes; (ii) which underlying factors connected with the surgeons were of importance; and (iii) how surgeon heterogeneity affected the comparison between RALP and RRP. We found large and statistically significant variation among individual surgeons regarding both functional and oncological outcomes. For functional outcomes the most important factor influencing heterogeneity was the surgeons’ previous experience, while annual caseload had the greatest impact on the oncological outcome. Adjusting for these surgeon volume-related factors had a statistically significant effect on the results when comparing RALP and RRP.

LAPPRO is a prospective, multicentre trial comparing outcomes after RRP and RALP, including 68 operating surgeons with varying experience. To investigate surgeon heterogeneity, we analysed patients operated on by all surgeons in the LAPPRO cohort as well as a subgroup of patients operated on by experienced surgeons with a previous caseload of more than 250 RPs. The definition of experienced surgeons was based on a previous report indicating that the learning curve for open surgery plateaus at 250 RRPs [21]. We found a considerable and statistically significant variation among individual surgeons’ case mix-adjusted outcomes for all surgeons but also for the subgroup of experienced surgeons. For functional outcomes the most important factor influencing the observed heterogeneity was previous experience, while annual volume had the greatest impact on heterogeneity for recurrence rate.

While heterogeneity in functional and oncological outcomes has been described earlier [15–17,22–24], underlying factors explaining such heterogeneity have not been reported in detail for RALP or RRP. In 2010, Bianco et al. [17] described variations among experienced surgeons in cancer control after RRP in a study from four high-volume centres. They found statistically significant heterogeneity in prostate cancer recurrence rate independent of surgeon experience. In a single-centre study, Vickers et al. [15] described a significant between-surgeon variation for potency and urinary continence 1 year after RRP in 1910 patients who were treated by 11 different surgeons. A Swedish population-based study looking at the effects of surgeon’s ($n=9$) variability on oncological and functional outcomes, also reported large heterogeneity in continence rate after RRP, but not for ED or recurrence rate [16]. In 2018, Huynh et al. [24] showed a 10-fold variation in 3-month continence rate when comparing five surgeons. Surgeon volume as an important factor for outcomes after RP was first described by Begg et al. [23] and has been commented on in follow-up papers [25] and in subsequent studies on learning curve [21,26–29]. Taken together, our results support most previous findings that surgeon heterogeneity and surgeon volume significantly affect long-term outcomes after RP. However, even though volume factors are important, most of the observed heterogeneity remained after taking these factors into account.

**Fig. 2** Surgeon heterogeneity and outcomes: (a) urinary incontinence, (b) erectile dysfunction and (c) recurrent disease. Rates (point estimates) and 95% CIs (horizontal lines) are adjusted for baseline patient and tumour characteristics (see statistical methods). Circles indicate a surgeon performing robot-assisted laparoscopic prostatectomy (RALP) and triangles indicate a surgeon performing open retropubic radical prostatectomy (RRP). Surgeons with at least 20 surgeries during the study period are illustrated.
Fig. 3 Surgeon heterogeneity and difference by surgical modality, (a) urinary incontinence, (b) erectile dysfunction and (c) recurrent disease. Odds ratios (point estimates) and 95% CIs (horizontal line) are all adjusted for baseline patient and tumour characteristics (see statistical analyses). The y-axis indicates which additional variables were included in the logistic regression model. The x-axis shows the odds ratio for open retropubic radical prostatectomy (RRP) vs robot-assisted laparoscopic prostatectomy (RALP).
into account. This means that experience and high volume is no guarantee of a favourable outcome. Although not fully explored, many other factors may contribute, including paying attention to every detailed step in the procedure and the set-up of the surgical training.

Since the primary aim of LAPPRO was to assess differences in outcomes by type of surgery, we also undertook analyses to evaluate how surgeon-dependent factors associated with surgeon heterogeneity affected the comparison between RALP and RRP. The additional adjustments for the surgeons’ previous experience and annual caseload had significant effects on the comparison for all outcomes. The impact was greatest for functional outcomes and changed whether the difference between techniques was statistically significant or not.

Using national register data, Hu et al. [7] compared the effects of minimally invasive RP and RRP and reported that the adding of surgeon volume to the case mix-adjusted base model did not affect functional outcomes, which is in contrast to our findings. Other cohort studies comparing RRP and RALP did not adjust for differences between the surgeons’ individual results [6,8,10–13,18]. In the only randomized trial comparing RRP and RALP published to date, similar functional outcomes were reported, whereas there was a difference regarding recurrence in favour of RALP (3% vs 9%) at 24-month follow-up [9]. However, the authors recommended caution in interpretation of the oncological outcomes because of the lack of standardization in postoperative management. Furthermore, with only one surgeon in each randomization arm, external validity was low and it was not possible to evaluate surgeon heterogeneity. Our results clearly show that surgeon volume significantly impacts long-term outcomes after RP and that it affects the comparison between techniques. Detailed knowledge is needed, not only of the cohort, but also of the surgeons, to minimize the risk of analysing differences between surgeons rather than true differences between the surgical techniques. There is a need for additional studies to better understand how the surgeon’s individual experience and skills affect the results when comparing different surgical techniques such as RALP and RRP.

Efforts to decrease the wide heterogeneity in outcomes are warranted, irrespective of surgical approach, and can be facilitated by continuously reporting and monitoring surgical outcomes in quality registers. Organizing training of new surgeons, defining basic skills criteria as well as a minimum of annual cases performed by an individual surgeon, and peer-to-peer observation in the operating room with feedback is critical.

Strengths of the present study include the large number of patients included (n = 3443), the high response rate to questionnaires [6,18] as well as the multicentre design and the large number of surgeons (n = 68), which is a prerequisite for the validity of outcomes and for an investigation of surgeon heterogeneity. The prospective nature of the data collection, the detailed data on surgeons’ experience as well as on peri-operative details such as nerve-sparing are additional strengths. The present study is unique in that we have explored the impact of different underlying factors explaining surgeon heterogeneity which have not been reported earlier in detail in a large prospective study.

The study is limited by the non-randomized design of the trial. The results represent a nationwide cohort including hospitals of different size and surgeons with different training background, which can be a potential limitation in terms of generalizability to other surgeons and settings around the world. In previous reports, we have described differences between the RALP and RRP cohorts regarding the frequency and various degrees of nerve-sparing [6]. We have also reported that stratification of the cohorts based on D’Amico risk groups affected outcome analyses [30]. Such differences between the RALP and RRP groups also indicate that direct comparison between the surgical methods must be carried out with caution. Results from previous subgroup analyses are not quite comparable with the data presented here because surgeons with less experience are also included in the present analyses.

In conclusion, we have demonstrated a large and statistically significant variation between individual surgeons in functional and oncological outcomes after RP. Although surgeons’ previous experience and annual caseload influenced heterogeneity significantly, a large degree of heterogeneity remained after taking these volume-related factors into account. Importantly, adjusting for surgeon volume affected whether there was an advantage associated with RALP or RRP, which indicates that studies comparing different surgical procedures should be interpreted with caution. Strategies to decrease surgeon heterogeneity must be prioritized.

Acknowledgements

This study was supported by research grants from the Swedish Cancer Society (2008/922, 2010/593, 2013/497, 2016/362), the Swedish Research Council (2012-1770, 2015-02483), Region Västra Götaland, Sahlgrenska University Hospital (ALFBGB grants 13875, 146201, 4307771; HTA–VGR 6011; agreement concerning research and education of doctors), the Mrs Mary von Sydow Foundation, and the Anna and Edvin Berger Foundation. Drs Martin Nyberg and Anders Bjartell were supported by research grants from Region Skåne, Sweden and Lund University (ALF 42202/2018). The work of Drs Sigrid Carlsson and Dan Sjöberg on this paper was supported in part by a Cancer Centre Support Grant from the National Cancer Institute made to Memorial Sloan Kettering Cancer Centre (P30-CA008748). Dr Sigrid Carlsson’s work was also supported in part by funds from the
Sidney Kimmel Centre for Prostate and Urologic Cancers, National Institutes of Health/National Cancer Institute Transition Career Development Award (K22-CA234400).

Conflicts of interest
None declared.

References
1 Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1173–23
2 Bill-Axelson A, Holmberg L, Garino H et al. Radical prostatectomy or watchful waiting in prostate cancer – 29-year follow-up. N Engl J Med 2018; 379: 2319–29
3 Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function (‘trifecta’). Urology 2005; 66(Suppl): 83–94
4 Johansson E, Steineck G, Holmberg L et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. Lancet Oncol 2011; 12: 891–9
5 Wallerstedt A, Nyberg T, Carlsson S et al. Quality of life after open radical prostatectomy compared with robot-assisted radical prostatectomy. Eur Urol Focus 2019; 5: 389–98
6 Haghlin E, Carlsson S, Stranne J et al. Urinary incontinence and erectile dysfunction after robotic versus open radical prostatectomy: a prospective, controlled nonrandomised trial. Eur Urol 2015; 68: 216–25
7 Hu J, Gu X, Lipsitz SR et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy: a systematic review. JAMA 2009; 302: 1557–64
8 Barry MJ, Gallagher PM, Skinner JS, Fowler FJ Jr. Adverse effects of robotic-assisted laparoscopic versus open retropubic radical prostatectomy among a nationwide random sample of medicare-age men. J Clin Oncol 2012; 30: 513–8
9 Coughlin GD, Yaxley JW, Chambers SK et al. Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19: 1051–60
10 Nossiter J, Sujenthiran A, Charman SC et al. Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England. Br J Cancer 2018; 118: 489–94
11 Ritch CR, You C, May AT et al. Biochemical recurrence-free survival after robotic-assisted laparoscopic vs open radical prostatectomy for intermediate- and high-risk prostate cancer. Urology 2014; 83: 1309–15
12 Herlemann A, Cowan JE, Carroll PR, Cooperberg MR. Community-based outcomes of open versus robot-assisted radical prostatectomy. Eur Urol 2018; 73: 215–23
13 Alemoazzafar M, Sanda M, Yecies D, Mucci LA, Stampfer MJ, Kenfield SA. Benchmarks for operative outcomes of open and robotic radical prostatectomy: results from the Health Professionals Follow-up Study. Eur Urol 2015; 67: 432–8
14 Tang K, Jiang K, Chen H, Chen Z, Xu H, Ye Z. Robotic vs. Retropubic radical prostatectomy in prostate cancer: a systematic review and an meta-analysis update. Oncotarget 2017; 8: 32237–57
15 Vickers A, Savage C, Bianco F et al. Cancer control and functional outcomes after radical prostatectomy as markers of surgical quality: analysis of heterogeneity between surgeons at a single cancer center. Eur Urol 2011; 59: 317–22
16 Carlsson S, Berglund A, Sjöberg D et al. Effects of surgeon variability on oncologic and functional outcomes in a population-based setting. BMC Urol 2014; 14: 25
17 Bianco FJ Jr, Vickers AJ, Cronin AM et al. Variations among experienced surgeons in cancer control after open radical prostatectomy. J Urol 2010; 183: 977–82
18 Nyberg M, Hugosson J, Wiklund P et al. Functional and oncologic outcomes between open and robotic radical prostatectomy at 24-month follow-up in the Swedish LAPPRO trial. Eur Urol Oncol 2018; 3: 536–60
19 Thorsteinsson T, Stranne J, Carlsson S et al. LAPPRO: a prospective multicentre comparative study of robot-assisted laparoscopic and retropubic radical prostatectomy for prostate cancer. Scand J Urol Nephrol 2011; 45: 102–12
20 Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. J Stat Softw 2015; 67: 48
21 Vickers AJ, Bianco FJ, Serio AM et al. The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst 2007; 99: 1171–7
22 Eastham JA. Do high-volume hospitals and surgeons provide better care in urologic oncology? Urol Oncol 2009; 27: 417–21
23 Begg CB, Riedel ER, Bach PB et al. Variations in morbidity after radical prostatectomy. N Engl J Med 2002; 346: 1138–44
24 Huynh LM, Skarecky D, Porter J et al. A randomized control trial of anti-inflammatory regional hypothermia on urinary continence during robot-assisted radical prostatectomy. Sci Rep 2018; 8: 16352
25 Trinh QD, Bjartell A, Freedland SJ et al. A systematic review of the volume-outcome relationship for radical prostatectomy. Eur Urol 2013; 64: 786–98
26 Vickers AJ, Savage CJ, Hruza M et al. The surgical learning curve for laparoscopic radical prostatectomy: a retrospective cohort study. Lancet Oncol 2009; 10: 475–80
27 Thompson JE, Egger S, Böhm M et al. Superior biochemical recurrence and long-term quality-of-life outcomes are achievable with robotic radical prostatectomy after a long learning curve–updated analysis of a prospective single-surgeon cohort of 2206 consecutive cases. Eur Urol 2018; 73: 664–71
28 Bravi CA, Tin A, Vertosick E et al. The impact of experience on the risk of surgical margins and biochemical recurrence after robot-assisted radical prostatectomy: a learning curve study. J Urol 2019; 202: 108–13
29 Sivaraman A, Sanchez-Salas R, Prapotnich D et al. Learning curve of minimally invasive radical prostatectomy: comprehensive evaluation and cumulative summation analysis of oncological outcomes. Urol Oncol 2017; 35: 149.e1–e6
30 Sooriakumaran P, Pini G, Nyberg T et al. Erectile function and oncologic outcomes following open retropubic and robot-assisted radical prostatectomy: results from the laparoscopic prostatectomy robot open trial. Eur Urol 2018; 73: 618–627

Correspondence: Anders Bjartell, Department of Urology, Skåne University Hospital, Jan Waldenströms gata 5, SE 205 02 Malmö, Sweden.

e-mail: anders.bjartell@med.lu.se

Abbreviations: ED, erectile dysfunction; RALP, robot-assisted laparoscopic prostatectomy; RP, radical prostatectomy; RRP, retropubic radical prostatectomy.